The Epidemiology of Human Chondrogenic Progenitor Cells

人类软骨祖细胞的流行病学

基本信息

批准号：
8925674
负责人：
George F Muschler
金额：
$ 63.65万
依托单位：
CLEVELAND CLINIC LERNER COM-CWRU
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-16 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8925674
关键词：
Address Adhesions Adult Allografting Biological Biological Assay Bone Marrow Cartilage Cell physiology Cells Chemicals Chondrocytes Clinical Communities Connective Tissue Cues Defect Enabling Factors Epidemiology Evaluation Fatty acid glycerol esters Future Growth Factor Health Hemorrhage Homing Human Image Image Analysis In Vitro Joints Knee Laboratories Lesion Marrow Methodology Methods Muscle Orthopedics Outcome Pathogenesis Patients Perforation Performance Periosteum Phenotype Population Prevalence Procedures Process Proliferating Research Resources Signal Transduction Site Source Stem cells Surface Surgical Flaps Synovial Membrane Testing Tissue Engineering Tissues Transplantation articular cartilage base bone cartilage development cartilage regeneration cartilage repair clinical practice design improved in vivo insight migration osteochondral tissue progenitor programs public health relevance repaired success tissue repair treatment strategy

项目摘要

DESCRIPTION (provided by applicant): This program seeks to advance the field of Cartilage Tissue Engineering by defining strategies and principles for selecting and optimizing available sources of chondrogenic connective tissue progenitors (CTP- Cs). It will also provide the tissue engineering community with a rigorous and standardized quantitative methodology for objective evaluation and comparison of cell sourcing and processing options. Successful repair or regeneration of cartilage tissue requires a source of CTP-Cs, i.e. native cells that are capable of chondrogenic differentiation. Cartilage repair strategies must rely on one of several cell sourcing strategies. CTPs with chondrogenic potential reside in cartilage, as well as bone marrow, periosteum, muscle, fat and other tissues. Several of these tissue sources have already been or are being exploited to provide cells for cartilage repair and regeneration procedures. Although articular cartilage tissue shows little intrinsic capacity to repair, some cells in both normal and diseased cartilage tissue can be induced to proliferate and differentiate to express a chondrocytic phenotype in vitro. Such cartilage-derived CTP-Cs have become central to several treatment strategies based on transplantation of freshly isolated cartilage tissue or culture-expanded cells into a cartilage defect. To date, cell sourcing decisions and cell processing or fabrication strategies have generally not been based on quantitative assays of the concentration, prevalence or biological potential of the available cell sources. This program addresses three opportunities to improve clinical practices: 1) Define the concentration, prevalence and biological potential of chondrogenic connective tissue progenitors (CTP-Cs) in and around the adult human knee (articular cartilage, fat pad, synovium, periosteum, subchondral bone and marrow). 2) Define the relationship between cartilage tissue health and the concentration, prevalence and biological potential of CTP- Cs in human cartilage. 3) Test the hypothesis that differences in in vitro performance between CTP-C sources predict differences in in vivo performance.

描述（由申请人提供）：该计划旨在通过定义选择和优化软骨结缔组织祖细胞（CTP-Cs）可用来源的策略和原则来推动软骨组织工程领域的发展。它还将为组织工程界提供严格且标准化的定量方法，用于客观评估和比较细胞来源和加工选项。软骨组织的成功修复或再生需要 CTP-C 来源，即能够软骨分化。软骨修复策略必须依赖于多种细胞来源之一策略。具有软骨形成潜力的 CTP 存在于软骨以及骨髓、骨膜、肌肉、脂肪和其他组织中。这些组织来源中的一些已经或正在被开发来提供用于软骨修复和再生过程的细胞。尽管关节软骨组织几乎没有表现出内在的修复能力，但正常和软骨组织中的一些细胞可以在体外诱导患病软骨组织增殖和分化以表达软骨细胞表型。这种源自软骨的 CTP-C 已成为多种治疗策略的核心，这些治疗策略基于将新鲜分离的软骨组织或培养扩增的细胞移植到软骨缺损中。迄今为止，细胞采购决策和细胞加工或制造策略通常不是基于对可用细胞来源的浓度、普遍性或生物潜力的定量分析。该计划提出了改善临床实践的三个机会：1）定义成人膝关节内部和周围（关节软骨、脂肪垫、滑膜、骨膜、软骨下骨）的软骨形成结缔组织祖细胞（CTP-C）的浓度、流行率和生物潜力和骨髓）。 2) 定义软骨组织健康与人体软骨中CTP-Cs的浓度、普遍性和生物潜力之间的关系。 3) 检验以下假设：CTP-C 来源之间体外性能的差异可预测体内性能的差异。